Radiopharm Theranostics and SHINE Technologies Announce Clinical Supply Agreement for Cancer Medical Isotope

SHINE will supply nec lutetium-177 for the clinical development of several programs for Radiopharm Theranostics

JANESVILLE, Wis. and SYDNEY, September 19, 2022 /PRNewswire/ — SHINE Technologies, a next-generation fusion technology company, and Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of diagnostic and therapeutic radiopharmaceuticals, today announced that they had entered into a clinical supply agreement. SHINE will supply Radiopharm with the isotope lutetium-177 without added support (Lu-177).

The isotope will be used by Radiopharm in the development of its clinical pipeline of diagnostic and therapeutic radiopharmaceuticals. Lu-177 is an important isotope used in multiple programs in Radiopharm’s portfolio.

“In one way or another, almost everyone has been touched by cancer. SHINE’s efforts in lutetium-177 are aimed at extending the lives of those most directly affected,” said Chris Vessel, General Manager of SHINE’s Therapeutic Division. “We are delighted that our isotopes are playing a vital role in Radiopharm Theranostics’ programs that aim to revolutionize cancer treatment.”

SHINE, an emerging leader in the production of this medical radioisotope, intends to be the only vertically integrated producer of Lu-177, aiming to provide a reliable and scalable supply independent of current supply chain constraints. . »

“Securing the supply of key isotopes continues to be a priority for our team, allowing us to accelerate our clinical programs unhindered,” said Ricardo Canevari, CEO and Managing Director of Radiopharm Theranostics. “Lutetium-177 is required for three of our most advanced assets and this clinical supply agreement with SHINE, an experienced nuclear technology player, is another important step in de-risking our business plan. “

About SHINE Technologies

Situated at Janesville, Wis., US, SHINE Technologies is a next-generation fusion technology company, deploying safe, cost-effective, and environmentally friendly systems for use in industrial imaging of components in aerospace, defense, transport, medicine, energy and more. SHINE’s proprietary isotope production processes create both molybdenum-99 and nec lutetium-177, each of which is used in multiple diagnostic and therapeutic medical procedures. Learn more about www.shinefusion.com and @shinefusion.

SOURCE SHINE Technologies, LLC

About John Tuttle

Check Also

New FDA draft guidelines aim to protect children participating in clinical trials

SILVER SPRING, MD., September 23, 2022 /PRNewswire/ — Today, the United States Food and Drug …